Project Grant R21AI201758
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $2.284 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on microbial interactions combating antibiotic-resistant bacteria (MI-CARB). The research employs a systems biology approach to understand pathogenesis of nosocomial infections caused by three pathogen groups: vancomycin-resistant enterococci (VRE),...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $617,438 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid cell-based diagnostic test for urinary tract infections and antimicrobial resistance screening. The project addresses the clinical need for point-of-care UTI diagnosis and antibiotic selection. Current diagnostic methods—urine analysis and culture—require 1–3 days for results and lack...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on April 1, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project examines the role of organelle membrane contact sites in macrophage antifungal immune responses, with particular focus on Candida albicans infection. Preliminary data indicate that the endoplasmic reticulum stress sensor IRE1A...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $777,498 to the University of Washington on May 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the structural basis of parasteric inhibition mechanisms targeting bacterial adhesins, specifically the fimbrial lectin FimH of uropathogenic E. coli. The project characterizes how monoclonal antibodies and de novo-designed miniproteins...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Alabama $234,000 on May 7, 2026, for Project Grant R21AI194156 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the role of amyloid-beta peptides in driving inflammation during urinary tract infections. The project investigates an emerging hypothesis that bacterial infection triggers accumulation of amyloid-beta in the kidney, leading to deleterious...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $3.252 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to generate pre-IND validation data for novel bacterial metabolism inhibitors targeting antimicrobial-resistant uropathogens that cause urinary tract infections. The project addresses escalating antimicrobial resistance in uropathogenic Escherichia coli, the leading cause of UTIs...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded Vanderbilt University $100,228.00 on December 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a Project Grant to investigate how intracellular Pseudomonas aeruginosa exploits host fatty acid metabolism during urinary tract infections. The funded research will identify mechanisms by which P. aeruginosa hijacks host fatty acid...
- The National Institute of Allergy and Infectious Diseases awarded Regents of the University of Michigan $411,078 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel antifungal compounds from symbiotic bacteria capable of combating drug-resistant Candida auris. The research exploits symbiotic bacteria—organisms that co-exist with and benefit their eukaryotic hosts—as a source of antifungal molecules with low mammalian toxicity. The...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $195,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI201758). The recipient will develop a urea-inducible library of 217 transcription factors in Proteus mirabilis, a bacterium responsible for up to 44 percent of long-term catheter-associated urinary tract infections and capable of causing urinary stone formation, catheter blockage, bacteremia, urosepsis, and death. The research constructs low-copy-number urea-driven expression plasmids to model how the pathogen senses its urinary tract environment and orchestrates genetic programming for fitness advantages within distinct urinary niches. Specific aims include building and testing the transcription factor library with in vitro human urine agar screening, and conducting proof-of-principle experiments using three selected induced regulators in a murine model of urinary tract infection. Work is performed at Ann Arbor, Michigan. The period of performance runs from September 1, 2026, through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $195.0k | 8/28/26 |